|
1) Barst RJ, Rubin LJ, McGoon MD, et al. Survival in primary pulmonary hypertension with long-term continuous intravenous prostacyclin. Ann Int Med. 1994; 121: 409-15
|
|
|
|
2) Fuster V, Steele PM, Edwards WD, et al. Primary pulmonary hypertension: natural history and the importance of thrombosis. Circulation. 1984; 70: 580-7
|
|
|
|
|
|
3) Humbert M, Sitbon O, Simonneau G. Treatment of pulmonary arterial hypertension. N Engl J Med. 2004; 351: 1425-36
|
|
|
|
|
4) Rich S, Kaufmann E, Levy PS. The effect of high doses of calcium-channel blockers on survival in primary pulmonary hypertension. N Engl J Med. 1992; 327: 76-81
|
|
|
|
|
|
5) Badesch DB, Abman SH, Simonneau G, et al. Medical therapy for pulmonary arterial hyper-tension: updated ACCP evidence-based clinical practice guidelines. Chest. 2007; 131: 1917-28
|
|
|
|
|
|
6) McLaughlin VV, McGoon MD. Pulmonary arterial hypertension. Circulation. 2006; 114: 1417-31
|
|
|
|
|
|
7) Christman BW, McPherson CD, Newman JH, et al. An imbalance between the excretion of thromboxane and prostacyclin metabolites in pulmonary hypertension. N Engl J Med. 1992; 327: 70-5
|
|
|
|
|
|
8) McLaughlin VV, Shillington A, Rich S. Survival in primary pulmonary hypertension: the impact of epoprostenol therapy. Circulation. 2002; 106: 1477-82
|
|
|
|
|
|
9) McLaughlin VV, Genthner DE, Panella MM, et al. Reduction in pulmonary vascular resistance with long-term epoprostenol (prostacyclin) therapy in primary pulmonary hypertension. N Engl J Med. 1998; 338: 273-7
|
|
|
|
|
|
10) Rich S, McLaughlin VV. The effects of chronic prostacyclin therapy on cardiac output and symptoms in primary pulmonary hypertension. J Am Coll Cardiol. 1999; 34: 1184-7
|
|
|
|
|
|
11) Barst RJ, McGoon M, McLaughlin V, et al. Beraprost therapy for pulmonary arterial hyper-tension. J Am Coll Cardiol. 2003; 41: 2119-25
|
|
|
|
|
|
12) Rosenzweig EB, Ivy DD, Widlitz A, et al. Effects of long-term bosentan in children with pulmo-nary arterial hypertension. J Am Coll Cardiol. 2005; 46: 697-704
|
|
|
|
|
|
13) Sasayama S, Kunieda T, Tomoike H, et al. Effects of the endothelin receptor antagonist bosentan on hemodynamics, symptoms and functional capacity in Japanese patients with severe pulmonary hypertension. Circ J. 2005; 69: 131-7
|
|
|
|
|
14) Galie N, Ghofrani HA, Torbicki A, et al. Sildenafil citrate therapy for pulmonary arterial hyper-tension. N Engl J Med. 2005; 353: 2148-57
|
|
|
|
|
|
15) Wilkins MR, Paul GA, Strange JW, et al. Sildenafil versus Endothelin Receptor Antagonist for Pulmonary Hypertension (SERAPH) study. Am J Respir Crit Care Med. 2005; 171: 1292-7
|
|
|
|
|
|
16) Abe K, Shimokawa H, Morikawa K, et al. Long-term treatment with a Rho-kinase inhibitor improves monocrotaline-induced fatal pulmonary hypertension in rats. Circ Res. 2004; 94: 385-93
|
|
|
|
|
|
17) Ogawa A, Nakamura K, Matsubara H, et al. Prednisolone inhibits proliferation of cultured pulmonary artery smooth muscle cells of patients with idiopathic pulmonary arterial hypertension. Circulation. 2005; 112: 1806-12
|
|
|
|
|
|
18) Date H, Kusano KF, Matsubara H, et al. Living-donor lobar lung transplantation for pulmonary arterial hypertension after failure of epoprostenol therapy. J Am Coll Cardiol. 2007; 50: 523-7
|
|
|
|
|
|
19) Schermuly RT, Dony E, Ghofrani HA, et al. Reversal of experimental pulmonary hyper-tension by PDGF inhibition. J Clin Invest. 2005; 115: 2811-21
|
|
|
|
|
|
20) Ghofrani HA, Seeger W, Grimminger F. Imatinib for the treatment of pulmonary arterial hyper-tension. N Engl J Med. 2005; 353: 1412-3
|
|
|
|
|
|
21) Bargagli E, Galeazzi M, Bellisai F, et al. Infliximab treatment in a patient with systemic sclerosis associated with lung fibrosis and pulmonary hypertension. Respiration. 2008; 75: 346-9
|
|
|
|
|
|
22) Klein M, Schermuly RT, Ellinghaus P, et al. Combined tyrosine and serine/threonine kinase inhibition by sorafenib prevents progression of experimental pulmonary hypertension and myocardial remodeling. Circulation. 2008; 118: 2081-90
|
|
|
|
|